Personalizing medicines to reduce bleeding after stent procedure
Part of Heart & circulation clinical trials.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a stent procedure (PCI) and have been on aspirin 81 mg plus prasugrel or ticagrelor as maintenance treatment
- You have been on this double medicine at least 30 days (if ongoing stable symptoms) or 3 months or longer (if you had an acute event)
- You can sign a written informed consent form
- You have not had a stent clot before, and you are not taking blood thinners like warfarin, apixaban, rivaroxaban, dabigatran, edoxaban, or long-term injections for clot treatment
- You do not have major bleeding/bleeding-clotting problems, severe liver or kidney problems on dialysis, uncontrolled body instability, known medicine allergy to clopidogrel, or pregnancy/breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether lowering the dose of your current blood thinner or switching to a different one (clopidogrel) is safer and works just as well after you've had a stent placed. It's designed for people who are already on two blood thinners and are doing well.
This trial tests if people who have been on two blood thinners (aspirin plus prasugrel or ticagrelor) for at least 90 days after getting a heart stent can safely switch to just one of those blood thinners. It aims to see if taking only one pill is as safe and effective as taking two.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.